APR 13, 2021 8:00 AM PDT

The "Unexpected" Reason Why COVID Antivirals Don't Work

WRITTEN BY: Tara Fernandez

Purdue University researchers have made a breakthrough finding that could explain why the disease is so hard to manage therapeutically. In what was described as a surprising discovery, they found that a specific immune pathway activated in the lung tissue during COVID infection contributes to hyper-inflammation in severe cases, rendering standard antivirals ineffective.

Since the beginning of the pandemic, scientists have been scrambling to identify antiviral drugs to treat COVID patients with severe and life-threatening symptoms. Unfortunately, until now, this search has dug up very few viable options. Antivirals such as Remdesivir and Ruxolitinib are notoriously ineffective at treating COVID patients.

To understand why these drugs fall short, Purdue University computer science expert Majid Kazemian and colleagues took a closer look at the gene expression fingerprints left by SARS-CoV-2 infections. The team made the unexpected observation that small immune proteins, typically synthesized by the liver, were being produced in the fine structures of the lung known as alveoli. These proteins, part of the immune complement system, normally help the antibodies combat infectious pathogens.

“We observed that SARS-CoV2 infection of these lung cells causes expression of an activated complement system in an unprecedented way,” explained Kazemian. 

“This was completely unexpected to us because we were not thinking about activation of this system inside the cells, or at least not lung cells. We typically think of the complement source as the liver.”

However, instead of protecting against the coronavirus, complement activation in the lung triggers uncontrolled and detrimental tissue hyper-inflammation, a trademark symptom of severe COVID-19.

These findings provide evidence for why targeting inflammation outside the lungs has been disappointing so far. Instead, a more targeted approach that inhibits the expression and activation of complement proteins in lung cells could yield better results. For example, the researchers found that pairing Remdesivir with Ruxolitinib inhibited the complement response much more effectively than a monotherapy of the drugs independently, using an in vitro model of alveolar cells.

Despite the promising preliminary data, follow-up experiments are needed to determine whether such drug combos would work well in patients. 

 


Sources: Science Immunology, Purdue University.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
DEC 15, 2020
Immunology
The Possibility of Improving an Older Adult's Response to Vaccines
DEC 15, 2020
The Possibility of Improving an Older Adult's Response to Vaccines
A recent study published in the eLife journal examined how they can improve older adults' responses to vaccines ...
DEC 28, 2020
Immunology
What Happens When Your Immune System Works Against You?!
DEC 28, 2020
What Happens When Your Immune System Works Against You?!
Our immune system is our army against any molecule that wants to invade our bodies like viruses, bacteria, and cancer. I ...
FEB 07, 2021
Microbiology
Positive Results From A Clinical Trial of an HIV Vaccine
FEB 07, 2021
Positive Results From A Clinical Trial of an HIV Vaccine
After years of effort, researchers are reporting that there were encouraging results from a phase 1 clinical trial which ...
MAR 31, 2021
Microbiology
Deep-Sea Microbes Are 'Invisible' to the Human Immune System
MAR 31, 2021
Deep-Sea Microbes Are 'Invisible' to the Human Immune System
Scientists took an exploratory journey to a place in the central Pacific Ocean in Kirbati called the Phoenix Islands Pro ...
APR 06, 2021
Immunology
Lymphoma Patient Cured by "Reeducating" their Immune System
APR 06, 2021
Lymphoma Patient Cured by "Reeducating" their Immune System
Australian researchers have used a breakthrough therapy to cure a patient diagnosed with a rare brain lymphoma, a form o ...
MAY 04, 2021
Immunology
One Vaccine to Rule Them All
MAY 04, 2021
One Vaccine to Rule Them All
There are currently five variants of concern in the U.S., genetically distinct forms of the COVID-causing coronavirus th ...
Loading Comments...